Andrew J Cutler

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 11

Top Topics

Major Depressive Disorder

Combination Therapy

Top Venues

Journal of child and adolescent psychopharmacology

Translational psychiatry

Journal of the American Psychiatric Nurses Association

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew J Cutler, Gregory W Mattingly, Vladimir Maletic
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Translational psychiatry 13 (1) (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology (2023)
Andrew J Cutler, Katsumi Suzuki, Brittney Starling, Kanan Balakrishnan, Marina Komaroff, Suzanne Meeves, Mariacristina Castelli, Ann C Childress
d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial. Journal of child and adolescent psychopharmacology 33 (5) (2023)
Andrew J Cutler, Gregory W Mattingly, Vladimir Maletic
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Translational psychiatry 13 (1) (2023)
Andrew J Cutler, Gregory W Mattingly, Vladimir Maletic
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Translational psychiatry 13 (1) (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology 33 (2) (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology 33 (2) (2023)
Andrew J Cutler, Gregory W Mattingly, Vladimir Maletic
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Translational psychiatry 13 (1) (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology 33 (2) (2023)
Andrew J Cutler, Katsumi Suzuki, Brittney Starling, Kanan Balakrishnan, Marina Komaroff, Mariacristina Castelli, Suzanne Meeves, Ann C Childress
Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study. Journal of child and adolescent psychopharmacology 32 (2) (2022)
Andrew J Cutler, Stanley N Caroff, Caroline M Tanner, Huda Shalhoub, William R Lenderking, Véronique Pagé, Ericha Franey, Chuck Yonan
Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study. Journal of the American Psychiatric Nurses Association (2021)